Clinical trials: REE
Gastroesophageal Reflux Disease, GERD
What is the Predictive Value of the Reflux Impact Scale
Gastric distress is a common phenomenon in our society. Heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn, Acid Regurgitation
- Trial name
- PREDICT (NCT00536328)
- Volunteers
- 938 people
- Sponsor
- AstraZeneca
Multiple Sclerosis
Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome
Multiple sclerosis (MS) is a common cause of severe neurological disability in young adults, resulting from an autoimmune interruption of both myelin and axons within the central nervous system (CNS).
- Trial name
- TERIS (NCT03122652)
- Testing
- Teriflunomide 14 MG Oral Tablet [Aubagio]
- Where
- 23 sites in France, Switzerland and 1 more
- Volunteers
- 125 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Chronic Schizophrenia, Schizoaffective Disorder
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or…
- Trial name
- NCT01450514
- Testing
- Pipamperone
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- PharmaNeuroBoost N.V.
Healthy
Effects of Dihydrocapsiate on Adaptive and Diet-Induced Thermogenesis With a High Protein Very Low Calorie Diet
The study is designed to determine the effects of a non-pungent supplement from sweet chilli pepper on resting metabolic rate and diet-induced thermogenesis (DIT) after a period of very low calorie intake over 4 weeks.
- Trial name
- NCT01142687
- Testing
- dihydrocapsiate capsule
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Schizophrenia, Schizoaffective Disorder
A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
The purpose of this study is to document the long-term safety of 25, 50 or 75 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to patients with schizophrenia or schizoaffective…
- Trial name
- NCT00558298
- Testing
- risperidone
- Volunteers
- 811 people
- Sponsor
- Janssen, LP
Radiologically Isolated Syndromes; Multiple Sclerosis
Comparison of Digital Biomarkers in Subjects With Radiologically Isolated Syndrome (RIS) and Multiple Sclerosis (MS) Patients With Clinically Normal Neurological Examination
Radiologically Isolated Syndrome (RIS) is the preclinical stage of Multiple Sclerosis (MS). It is the incidental discovery of white matter abnormalities on brain or spinal cord magnetic resonance imaging (MRI), whose shape…
- Trial name
- SPAM 3 (NCT07135752)
- Testing
- Precision assessment
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Hypothyroidism
Hypothyroidism, Metabolism and Quality of Life - Focus on QOL, REE, Cognitive Function and Body Composition
This project has the following primary aims: The main objective is to delineate the association between changes in Resting energy expenditure (REE) and QOL in hypothyroid patients before and after one year of L-T4 treatment.
- Trial name
- HYMAQ (NCT02891668)
- Testing
- Levothyroxine treatment
- Where
- Denmark
- Volunteers
- 42 people
- Sponsor
- Herlev Hospital
Neoplasms, Lung
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
This is an early-phase clinical study investigating a new combination treatment, Risvutatug rezetecan (Ris-Rez) given with ivonescimab for adults with advanced solid cancers.
- Trial name
- NCT07602855
- Testing
- Risvutatug rezetecan, Ivonescimab
- Where
- 4 sites in United States, Japan
- Volunteers
- 184 people
- Sponsor
- GlaxoSmithKline
Primary Osteoporosis
Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis
To evaluate the efficacy and safety of R484iv by intravenous intermittent administration to patients with primary osteoporosis in comparison with sodium risedronate hydrate (RIS) by oral administration every day.
- Trial name
- NCT00447915
- Testing
- ibandronic acid 0.5mg, 1.0mg ibandronic acid, 2.5mg RIS
- Where
- 4 sites in Japan
- Volunteers
- 1,265 people
- Sponsor
- Chugai Pharmaceutical
Brain Death, Brain Injuries
Resting Energy Needs in Brain Dead Patients (reSting EneRgy nEeds iN brAin DEad Patients)
The study will examine the resting energy need (REE) in patients suffering from brain damage. For the measurement of REE will be used a metabolic computer (which with continuous recording of breath-to-breath volume (Vt)…
- Conditions
- Brain Death, Brain Injuries, Brain Edema, Brain Hemorrhage
- Trial name
- SERENADE (NCT05070182)
- Testing
- REE - Resting Energy Expenditure, Transcranial Doppler
- Where
- Greece
- Volunteers
- 66 people
- Sponsor
- Aristotle University Of Thessaloniki
Multiple Sclerosis
Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)
Multiple sclerosis (MS) witnessed relevant therapeutic progress in the last decade. Following the extraordinary progress in the treatment of relapsing-remitting (RR) multiple sclerosis (MS), two major unmet needs remain to be…
- Trial name
- NCT03888924
- Testing
- Bacille Calmette-Guerin vaccine
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- S. Andrea Hospital
Comparative Study, REE
Comparative Evaluation of smART+ REE Module to an FDA-cleared Device, for REE Calculation in ICU Patients
A prospective, single-center, comparative evaluation of smART+ REE Module to an FDA-cleared REE Module device, for REE calculation in ICU Patients.
- Conditions
- Comparative Study, REE, Resting Energy Expenditure
- Trial name
- (REE) (NCT07165080)
- Testing
- smART+ REE
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- ART Medical Ltd.
Energy Metabolism, Heart Rate
Effects of a Thermogenic Dietary Supplement on Metabolic, Hemodynamic, and Mood Responses
This a randomized, double blind, placebo controlled, crossover design study which measures the effect of an available thermogenic dietary supplement on resting energy expenditure (REE), blood pressure and heart rate, and mood…
- Conditions
- Energy Metabolism, Heart Rate, Blood Pressure, Mood
- Trial name
- NCT03678116
- Testing
- Caffeine (plus Teacrine and Cayenne), Caffeine (plus Teacrine)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Mary Hardin-Baylor
Gastrointestinal Neoplasms
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or…
- Trial name
- NCT06885034
- Testing
- Risvutatug Rezetecan
- Where
- 85 sites in United States, Australia and 17 more
- Volunteers
- 346 people
- Sponsor
- GlaxoSmithKline
Infant,Premature
Impact of Protein Supplementation to Mother Milk on Resting Energy Expenditure (REE) in Growing Healthy Preterm Infants.
Resting Energy Expenditure is the amount of energy, usually expressed in Kcal required for a 24 hour period by the body during resting conditions. It is closely related to, but not identical to, basal metabolic rate.
- Trial name
- NCT03501485
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Indirect Calorimetry, Mechanical Ventilation
Effect of PEEP on Indirect Calorimetry in Critically Ill Patients
Indirect calorimetry is used in intensive care to measure how much oxygen a patient consumes and how much carbon dioxide is produced.
- Conditions
- Indirect Calorimetry, Mechanical Ventilation, Positive End-Expiratory Pressure
- Trial name
- IC-PEEP (NCT07796698)
- Testing
- Protocolized PEEP Adjustment
- Volunteers
- 20 people
- Sponsor
- Vastra Gotaland Region
Neoplasms, Prostate
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
This study aims to evaluate how well risvutatug rezetecan (Ris-Rez) works in treating prostate cancer compared to best supportive/standard of care (BSC) which may include a hormone therapy with an androgen receptor pathway…
- Trial name
- NCT07802704
- Testing
- Risvutatug rezetecan (Ris-Rez), Enzalutamide, Abiraterone
- Where
- 6 sites in Australia, Canada and 2 more
- Volunteers
- 684 people
- Sponsor
- GlaxoSmithKline
Peritonitis, Resting Energy Expenditure
The Relationship Between the Change of Resting Energy Expenditure and Nutritional Status .
Peritonitis is a common and devastating complication in patients on peritoneal dialysis (PD). It is a known fact that persistent inflammatory state and nutritional deterioration are closely associated with increased mortality in…
- Conditions
- Peritonitis, Resting Energy Expenditure, Nutrition
- Trial name
- NCT03511950
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Schizophrenia, Schizoaffective Disorder
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
The purpose of this study is to document the long-term safety of 25, 37.5, or 50 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to subjects with schizophrenia or schizoaffective…
- Trial name
- NCT00495118
- Testing
- risperidone
- Volunteers
- 314 people
- Sponsor
- Janssen, LP
Cancer
PRelationship Between Physical Activity and Cancer Ris
This protocol is a sub-study of the ongoing "Protect Health and Reduce Cancer Risk" study conducted in Shanghai, China, and sponsored by the Shanghai Cancer Institute, Vanderbilt University, and the National Cancer Institute.
- Trial name
- NCT00521651
- Where
- 2 sites in United States, China
- Volunteers
- 620 people
- Sponsor
- National Cancer Institute (NCI)